Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01976507 · ClinicalTrials.gov registry record · Phase 4
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
A Phase 4 study of Atrial Fibrillation and Atrial Flutter, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 101
- Enrollment target
- 1
- Study location
NCT01976507: Completed Phase 4 study of Atrial Fibrillation and Atrial Flutter, sponsored by Vanderbilt University Medical Center.
NCT01976507 is a Phase 4 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 101 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01976507, a Phase 4 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures.
Conditions Studied
Interventions
- DRUG dabigatran etexilate mesylate
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
What the finished NCT01976507 record still lists
NCT01976507 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which dabigatran etexilate mesylate is the first listed.
NCT01976507 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01976507 about?
NCT01976507 is a clinical study titled "Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism". The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation ...
What is the current status of trial NCT01976507?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 101 participants. The study started on 2013-10. Estimated completion is 2016-12.
What conditions does trial NCT01976507 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
What interventions are being tested in trial NCT01976507?
The interventions under investigation include: dabigatran etexilate mesylate (DRUG).
Who is sponsoring clinical trial NCT01976507?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01976507 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01976507's enrollment target sits among peer trials
101 138th of 202 higher than 65 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia